Company intelligence / Profile preview

Aperon Biosystems

Menlo Park, California, United States

Ownership: Private
Development stage: Other

Overview

Aperon Biosystems was a medical technology company focused on developing long-term, implantable continuous glucose monitoring (CGM) systems. The company's core technology utilized optical biosensors designed to provide accurate, real-time glucose readings for patients with diabetes. By leveraging advanced sensor chemistry and miniaturized hardware, Aperon aimed to reduce the need for frequent finger-stick calibrations. In 2006, the company was acquired by Dexcom, a leader in the CGM market, to integrate its intellectual property and sensor capabilities into Dexcom's product pipeline.

Therapeutic areas: Endocrinology
Modalities: Device
Industry: Physiological Monitoring

Beyond the preview

Go deeper on Aperon Biosystems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aperon Biosystems.

Explore the full profile